(Q41954508)

14 October 2017

Compliance with RSV prophylaxis: Global physicians' perspectives (English)

1 reference

14 October 2017

Kari S Anderson

1

1 reference

14 October 2017

Victoria M Mullally

series ordinal

2

1 reference

14 October 2017

Linda M Fredrick

series ordinal

3

1 reference

14 October 2017

Andrew L Campbell

series ordinal

4

1 reference

14 October 2017

language of work or name

English

0 references

publication date

3 November 2009

1 reference

Patient Preference and Adherence

14 October 2017

1 reference

14 October 2017

3

1 reference

14 October 2017

195-203

1 reference

Creative Commons Attribution-NonCommercial 3.0 Unported

14 October 2017

start time

1 July 2009

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Palivizumab and respiratory syncytial virus immune globulin intravenous for the prophylaxis of respiratory syncytial virus infection in high risk infants.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778415

Development, implementation, and evaluation of a community- and hospital-based respiratory syncytial virus prophylaxis program

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778415

Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections

5 June 2018

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778415

5 June 2018

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778415

Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778415

An update on respiratory syncytial virus epidemiology: a developed country perspective

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778415

Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778415

Risk of primary infection and reinfection with respiratory syncytial virus

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778415

Direct medical costs of bronchiolitis hospitalizations in the United States.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778415

A 4-year survey on palivizumab respiratory syncytial virus (RSV)-prophylaxis: how can compliance be improved?

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778415

Compliance with prophylaxis for respiratory syncytial virus infection in a home setting

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778415

Parental emotional and time costs predict compliance with respiratory syncytial virus prophylaxis

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778415

Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778415

Home delivery of palivizumab: outcomes and compliance in regional preterm infants.

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2778415

Closer to home: local care improves compliance with RSV prophylaxis in high-risk infants

18 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19936162

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19936162

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Factors predicting compliance with palivizumab in high-risk infants

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19936162

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.2147/PPA.S5696

1 reference

14 October 2017

1 reference

14 October 2017

PubMed publication ID

19936162

1 reference